Adrenal and thyroid function in the fetus and preterm infant

Hye Rim Chung, MD
Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea

Adrenal and thyroid hormones are essential for the regulation of intrauterine homeostasis, and for the timely differentiation and maturation of fetal organs. These hormones play complex roles during fetal life, and are believed to underlie the cellular communication that coordinates maternal-fetal interactions. They serve to modulate the functional adaptation for extrauterine life during the perinatal period. The pathophysiology of systemic vasopressor-resistant hypotension is associated with low levels of circulating cortisol, a result of immaturity of hypothalamic-pituitary-adrenal axis in preterm infants under stress. Over the past few decades, studies in preterm infants have shown abnormal clinical findings that suggest adrenal or thyroid dysfunction, yet the criteria used to diagnose adrenal insufficiency in preterm infants continue to be arbitrary. In addition, although hypothyroidism is frequently observed in extremely low gestational age infants, the benefits of thyroid hormone replacement therapy remain controversial. Screening methods for congenital hypothyroidism or congenital adrenal hyperplasia in the preterm neonate are inconclusive. Thus, further understanding of fetal and perinatal adrenal and thyroid function will provide an insight into the management of adrenal and thyroid function in the preterm infant.

Key words: Premature infant, Thyroid, Adrenal glands

Introduction

Adrenal and thyroid gland hormones are essential for the regulation of intrauterine homeostasis and timely differentiation and maturation of fetal organs; these hormones provide the cellular communications that coordinate maternal-fetal interactions. During the perinatal period, they serve to modulate functional adaptations for extrauterine life.

Over recent decades, the survival rate of preterm infants has improved, yet preterm infants continue to present with abnormal thyroid and cortisol axes. Infants with endocrine abnormalities are at an increased risk of abnormal development and morbidity. As the physiology of preterm infants differs from that of term infants and older children, and normal physiological hormone levels of preterm infants at different gestational ages (GAs) remain unclear, no definitive management of endocrine problems in preterm infants has been determined as yet.

This article reviews current understanding of the maturation of fetal adrenal and thyroid glands, and the roles of the adrenal and thyroid hormones during the infant’s adaptation to extrauterine life; interpretation of clinical findings associated with these hormones in preterm infants is also discussed.
Fetal adrenal gland

The fetal adrenal gland exhibits a remarkable transformation in size, morphology, and function during the fetal and perinatal period. In contrast to the adrenal medulla, which is derived from the neuroectoderm, the adrenal cortex is of mesodermal origin. The primitive adrenal glands can be recognized by 3 to 4 weeks of gestation. The fetal adrenal gland is composed of three functional zones: a fetal zone (FZ), a transitional zone, and an outer definitive zone. The FZ mainly produces androgens, the transitional zone contains enzymes for cortisol production, and the definitive zone produces mineralocorticoids. The FZs become well differentiated by 9 to 12 weeks of gestation, and are capable of active steroidogenesis. The fetal adrenal gland grows rapidly; the combined glandular weight is approximately 8 g at term, at which time the FZ makes up about 80% of the mass of the gland, with a relative size that is 10 to 20 folds that of the adult adrenal gland. Soon after birth, the fetal adrenal gland undergoes rapid involution due to the rapid disappearance of the FZ; in contrast, the definitive zone, which comprises an inner zona fasciculata and an outer zona glomerulosa, proliferates.

The fetal adrenal gland expresses five steroidogenic enzymes: 17-hydroxylase and 17, 20-desmolase (CYP17 or P450c17), 21-hydroxylase (CYP21A2 or P450c21), cholesterol side-chain cleavage (CYP11A1 or P450scc), aldosterone synthase (CYP11B2 or P450c11), and 3β-hydroxysteroid dehydrogenase (CYP19A1). Since the FZ has relatively high steroid sulfotransferase activity and low 3βHSD activity, the major steroid products of the fetal adrenal gland are dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), and there is a limited amount of cortisol and aldosterone (Fig. 1). Fetal steroidogenesis is largely programmed to produce inactive products, and provide DHEA substrates for placental estrone and estradiol production. There is complementary activity between the enzymes involved in steroid formation and transformation between the placental and fetal compartments (Figs. 1, 2).

Prior to 23 weeks gestation, the human fetal adrenal cortex is unable to produce cortisol de novo and normally does not do so until as late as 30 weeks gestation. Near term, the fetal cortisol production rate in the blood per unit body weight is similar to that in the adult. About two thirds of fetal cortisol is derived from the fetal adrenal glands, and one third is derived from placental transfer. Fetal cortisol is converted to cortisone through an 11β hydroxysteroid dehydrogenase (11βHSD) in fetal tissues, and by midgestation, levels of circulating cortisone are 4 to 5 folds higher than cortisol concentrations.

Fetal steroidogenesis is regulated by the hypothalamic-pituitary-adrenal (HPA) axis. The adrenocorticotropic hormone (ACTH) feedback control system matures progressively during the second half of gestation and early neonatal period.

The steroid hormones produced by the fetal adrenal gland play key roles in the maintenance of pregnancy, intrauterine homeostasis, fetal maturation, and the initiation of parturition.

Fetal thyroid gland

The primordium of the human thyroid, which is derived from the epithelium of the pharyngeal floor, is initially recognizable at 16 to 17 days of gestation. The primitive stalk connecting the primordium with the pharyngeal floor elongates into the
thyroglossal duct; cells from the lower portion of thyroglossal duct differentiate into thyroid tissue\textsuperscript{12}.

Embryogenesis of the human thyroid gland is largely completed by 10 to 12 weeks gestation, at which point tiny follicle precursors are visible\textsuperscript{19}. Thyroid hormones are detectable in fetal serum by 12 weeks gestation; at that point, both thyroxine (T4) and triiodothyronine (T3) are measurable; however, a large proportion of detectable hormones derive from the mother through placental transfer\textsuperscript{20}. During gestation, there is a gradual increase in the levels of thyroid hormones. While thyroglobulin (TG) can be identified in the fetal thyroid gland as early as the 5th week, maturation of TG secretion takes much longer\textsuperscript{11,22}. While iodide concentrating capacity can be detected in the thyroid of the 10- to 11-week fetus, the capacity of the fetal thyroid gland to reduce iodide trapping in response to excess iodide does not appear until 36- to 40-week gestation\textsuperscript{23}.

The fetus has detectable levels of thyroid-stimulating hormone (TSH) at GA 12 weeks. There is a moderate increase in TSH over the last two trimesters to levels of 6 to 8 mU/L at the time of delivery\textsuperscript{24}. The fetal thyrotroph responds to thyrotropin-releasing hormone (TRH) as early as 25 weeks gestation\textsuperscript{24}. The maturation of the negative feedback control of thyroid hormone synthesis occurs around midgestation\textsuperscript{23,24} (Fig. 3).

During gestation, circulating concentrations of T4 and the active metabolite T3 are low, while the inactive metabolites, reverse T3 (rT3) and T3 sulfate, are high. This pattern is a consequence of both immaturity of the hypothalamic-pituitary-thyroid axis, and coordinated adjustments in the deiodinase system. The level of type 1 iodothyronine deiodinase (D1), which catalyzes T4 to T3 conversion, is low throughout gestation. Levels of type 2 deiodinase (D2), which converts T4 to T3, and type 3 deiodinase (D3), an inactivating deiodinase that converts T4 to rT3, are high\textsuperscript{25}. Despite low concentrations of circulating T3, by 20- to 26-week gestation T3 levels in the fetal brain are approaching 60\%–80\% of adult values. While the physiological significance of low circulating T3 concentrations throughout gestation is unknown, it has been suggested that its function may be to avoid tissue thermogenesis and potentiate the anabolic state of the rapidly growing fetus\textsuperscript{26}.

The placenta produces various hormones that can influence the fetal thyroid gland. The most important role of the placenta, however, is in regulating the passage of hormones and drugs from the mother to the embryo, a process that influences the fetal thyroid gland (Fig. 2).

Fetal anterior pituitary

Rathke’s pouch separates from the primitive pharyngeal stomodeum by 5-week gestation\textsuperscript{27}. The bony floor of the sella turcica is present by 7 weeks of gestation. Intact hypothalamic-pituitary portal vessels are present by 12 to 17 weeks of gestation. Maturation of the pituitary portal vascular system continues, extending to 30- to 35-weeks of gestation\textsuperscript{12}.

Role of endocrine system in transition to extrauterine life

After delivery, the neonate must initiate breathing and defend against hypothermia, hypoglycemia, and hypocalcemia, as the placental supply of energy and nutrients are abruptly removed. Fetal hormones, especially from the adrenal cortex and thyroid gland, rapidly respond to these changes.

Cortisol surge

Human fetal cortisol levels tend to be as low as 5–10 μg/mL until about 30-week gestation. Cortisol levels increase progressively, reaching ~20 μg/mL by 36 weeks of gestation, and 45 μg/mL at term. Cortisol increases further during labor, peaking to levels of ~200 μg/mL several hours after term delivery\textsuperscript{4,28}. This cortisol surge is mediated by a decrease in the conversion of cortisol to cortisone, with a simultaneous increase in cortisol production by the fetal adrenal gland. Cesarean section of the unlabored fetus blunts the postnatal rise in cortisol\textsuperscript{29}; also, during preterm birth, the cortisol responses are attenuated because of the immaturity and unresponsiveness of the adrenal gland\textsuperscript{29}.

The cortisol surge augments surfactant synthesis in lung tissue, increases reabsorption of liquid in the lung, increases
methylation of norepinephrine to epinephrine, increases conversion of T4 to T3, facilitates ductus closure, induces maturation of several enzymes and transport processes of the small intestine, and stimulates maturation of hepatic enzymes. Prenatal inflammation, as observed in chorioamnionitis, leads to adrenal stimulation, which results in increased cortisol secretion.

**Extrauterine thyroid adaptation**

During parturition, the neonate must rapidly convert from the fetal state of predominant thyroid hormone inactivation to a state of relative thyroid hyperactivity; this is initiated by an abrupt increase in hypothalamic TRH and pituitary TSH secretion. The cold-stimulated TRH-TSH surge is short-lived and peaks at 30 minutes, with peak concentrations as high as 60 to 70 µU/L; thereafter, serum TSH concentrations progressively decrease to normal infant levels by 3 to 5 days, while serum-free T4 levels remain elevated for several weeks.

While acute ablation of thyroid function at birth has not been shown to greatly alter thermogenesis or cardiovascular adaptation, chronic inhibition of thyroid function prior to birth has been shown to interfere with postnatal cardiovascular adaptation and thermogenesis in newborn lambs. These results show that thyroid hormones play an important role in the preparation for birth, rather than in modulating endocrine adaptation to birth. Preterm infants have a blunted TSH surge, with very low levels of plasma T3 and T4, relative to term infants.

**Adrenal gland of preterm infants**

The main functions of the postnatal adrenal gland are to regulate protein, carbohydrate, lipid, and nucleic acid metabolism; maintain vascular responsiveness to circulating vasconstrictors; oppose the increase in capillary permeability during acute inflammation; regulate extracellular water by reducing movement of water into cells and promoting water excretion; suppress the inflammatory response; and modulate central nervous system processing and behavior.

Activation of the HPA axis is crucial in maintaining homeostasis in response to stress; however, their adrenal glands have a transient inability to maintain cortisol homeostasis. TAP is typically transient, and adrenal function tends to return to normal by 2-week postpartum. Therefore, glucocorticoid-responsive hypotension is not considered a common phenomenon in this population beyond 2-week postpartum. However, preterm infants sometimes develop late-onset glucocorticoid-responsive circulatory collapse. The pathophysiology of late-onset adrenal insufficiency in preterm infants (AIP) is not due to an absolute deficiency of cortisol production; instead, it may be due to a limited ability to synthesize sufficient cortisol for the corresponding degree of clinical stress. Clinical predictors of AIP include hypotension, oliguria, hyponatremia, lung edema, increased demand for oxygen in the absence of infection, hypovolemia, anemia, and the reopening of a patent ductus.
arteriosus.

There are no definitive diagnostic criteria for AIP. A presumptive diagnosis can be made in case the clinical picture indicates adrenal insufficiency, inappropriately low serum cortisol levels, and rapid recovery from signs of adrenal insufficiency following cortisol replacement. A serum cortisol level of <15 μg/dl is frequently used for diagnosis of AIP. This level was based on relative adrenal insufficiency in critically ill adults and a study of critically ill term neonates that demonstrated improvement in hemodynamic parameters with hydrocortisone therapy, selectively in patients with initial cortisol concentrations of <15 μg/dl. A cortisol increase of <9 μg/dl in response to low dose adrenocorticotropic (ACTH) stimulation (1 μg/kg of synthetic ACTH) is also used for the diagnosis of AIP. However, in preterm infants, neither baseline cortisol <15 μg/dl nor Δ-cortisol <9 μg/dl were associated with the presence of relative adrenal insufficiency between days 5 and 7 postpartum. Some authors have recommended measuring the cortisol levels in serum or saliva in response to a corticotropin releasing hormone (CRH) test (1 μg/kg of hCRH) as a reliable method to evaluate the HPA axis in the preterm infant.

Hydrocortisone is greatly preferred over dexamethasone for treatment of AIP, because it has a limited effect on suppression of growth, and influences both glucocorticoids and mineralocorticoids. Various dosages and durations of hydrocortisone therapy have been used for replacement of AIP (Table 1). Further studies are warranted in order to verify the diagnostic criteria and optimal treatment of AIP.

### 2. Screening for congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH), which is caused by 21-hydroxylase deficiency, is an inherited metabolic disorder that affects 1 per 16,000 neonates. Mass screening of neonates for 21-hydroxylase deficiency identifies both male and female infants, prevents incorrect sex assignment, and decreases mortality and morbidity due to salt-wasting crisis. Most newborn screening programs measure 17-hydroxyprogesterone (17-OHP) from dried blood spots on filter paper; however, 17-OHP measurement has a high false positive rate in preterm infants.

The mechanisms underlying high 17-OHP concentrations in preterm infants are unclear, because 21-hydroxylase is actively expressed during early midgestation and 3β-HSD is expressed during late midgestation. Possible explanations for the increased levels of 17-OHP in preterm infants include an increase in the conversion of cholesterol to pregnenolone due to increased ACTH from postnatal stress; decrease in conversion of 11-deoxycortisol to cortisol due to delayed expression of 11β-hydroxylase; and decrease in the excretion of steroid metabolites in the kidney. Another probable explanation is that there is cross-reactivity while measuring 17-OHP, with other steroid metabolites such as 17-hydroxypregnalone and its sulfated metabolites.

Conversely, antenatal corticosteroid administration can interfere with CAH screening programs, because corticosteroids are known to suppress the HPA axis. Since betamethasone and dexamethasone are similar in their ability to cross the placenta and suppress the fetal pituitary-adrenal axis, the use of antenatal corticosteroids may increase the risk of lowering 17-OHP levels in the blood spot, thus leading to false-negative results.

While screening preterm infants for CAH, the rates for false positive and false negative results are high; however, there is a low risk of missing a case of CAH that might lead to a salt-wasting crisis in the neonatal intensive care unit. Rescreening of preterm infants with elevated 17-OHP levels, with careful monitoring of the clinical status during intervals, is necessary.

<table>
<thead>
<tr>
<th>Source</th>
<th>No.</th>
<th>GA (wk)</th>
<th>Postnatal age (day)</th>
<th>Serum cortisol (μg/dL)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seri et al. (2001)</td>
<td>21</td>
<td>26.9±3.9</td>
<td>11.3±13.1</td>
<td>ND</td>
<td>HC 2 mg/kg/day in 16 infants</td>
</tr>
<tr>
<td>Noori et al. (2006)</td>
<td>24</td>
<td>26 (23–34)</td>
<td>2 (1–24)</td>
<td>ND</td>
<td>Dexamethasone 0.1 mg/kg followed by 0.05 mg/kg intravenously every 12 hr for 5 additional doses</td>
</tr>
<tr>
<td>Ng et al. (2006)</td>
<td>HC (24) Placebo (24)</td>
<td>&lt;32</td>
<td>11 (8–15)</td>
<td>ND</td>
<td>HC 1 mg/kg every 8 hr for 5 days</td>
</tr>
<tr>
<td>Masumoto et al. (2008)</td>
<td>11</td>
<td>26.8±2.4</td>
<td>13.1±4.1</td>
<td>6.6±4.1</td>
<td>HC 1–2 mg/kg/dose</td>
</tr>
<tr>
<td>Choi et al. (2011)</td>
<td>12</td>
<td>30.6±2.4</td>
<td>19±7</td>
<td>11.6±4.1</td>
<td>HC 4 mg/kg/day for 1–2 days → 2 mg/kg/day for 1–2 days → 1 mg/kg/day for 1–2 days</td>
</tr>
<tr>
<td>Lee et al. (2013)</td>
<td>16</td>
<td>28±2</td>
<td>20±11</td>
<td>5.6±2.5</td>
<td>ND</td>
</tr>
<tr>
<td>Lee et al. (2013)</td>
<td>44</td>
<td>26.0±1.9</td>
<td>16.5 (5–158)</td>
<td>ND</td>
<td>HC loading dose: 3–5 mg/kg/day → 3 mg/kg/day → 1 mg/kg/day</td>
</tr>
</tbody>
</table>

**GA**: gestational age; **HC**: hydrocortisone; **ND**: not described.

*Age of initiation of corticosteroid treatment. Serum cortisol levels at the time of clinical manifestation of adrenal insufficiency. Mean±standard deviation. Median (range).
Thyroid function of preterm neonate

Postnatal thyroid function of preterm infants differs from that of term infants. Blunted postnatal TSH surges and low serum T4 levels are frequently observed in preterm neonates; this is generally referred to as hypothyroxinemia of prematurity\(^{56}\). In contrast to typical congenital hypothyroidism, initial screening indicates a normal TSH level, followed by delayed TSH elevation in some preterm infants\(^{58}\).

The main factors that influence thyroid function in preterm infants are immaturity of the hypothalamic-pituitary-thyroid axis, immature thyroid hormone synthesis, immature thyroid hormone metabolism, and systemic diseases. Insufficient or excessive iodine intake also influence preterm thyroid function\(^{59}\).

1. Hypothyroxinemia and delay in TSH elevation

Transient hypothyroxinemia of prematurity (THOP) is a condition that primarily affects preterm infants born at less than 30 weeks of gestation, and is characterized by low levels of circulating thyroid hormones despite normal levels of TSH\(^{56}\).

A blunted TSH surge after birth is one of the reasons for low T4 levels in the preterm infant\(^{50,51}\). The other reason is reduced storage of iodine, which can exist due to prematurity\(^{50,51}\). In addition, very low birth weight infants usually have various systemic diseases and are given drugs such as dopamine, dobutamine, and morphine that affect the hypothalamic-pituitary-thyroidal axis. Thus, TSH levels are not representative of overall thyroid function in preterm infants.

The depth of the nadir and length of time before THOP resolves is related to GA. This condition usually resolves within 2 to 3 weeks, with progressive maturation of the hypothalamic-pituitary-thyroid axis\(^{56}\). Although no consensus exists for THOP reference ranges, prevalence rates have been reported to be 35%–85% in very preterm infants\(^{49}\).

Although transiently low levels of thyroid hormones are associated with higher rates of cerebral palsy and cognitive impairment in preterm infants, studies have not demonstrated the benefits of thyroid hormone replacement (Table 2). In a meta-analysis, prophylactic thyroid hormone replacement in preterm infants was not shown to be beneficial in reducing neonatal mortality or morbidity, or in improving neurodevelopmental outcomes\(^{49}\).

The incidence of persistent hypothyroidism does not differ among preterm and term newborns; however, transient hypothyroidism is considerably more prevalent\(^{50}\). The estimated incidence of delayed TSH elevation is up to 12% in preterm infants\(^{48,49}\). Although the timing of this elevation varies, it usually develops between 2 and 6 weeks of age in most cases. Although the reasons for delayed TSH elevation in the preterm infant may be complex, iodine deficiency or excess are the likely reasons for transient hypothyroidism in the preterm infant.

Table 2. Summary of published studies on the outcomes of thyroid hormone supplementation in preterm neonates

<table>
<thead>
<tr>
<th>Source</th>
<th>Thyroid hormone replacement (n)</th>
<th>GA (wk) Evaluation</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chowdhry et al.(^{50}) (1984)</td>
<td>L-T4 10–15 μg/kg, IM Treated (12), Untreated (11)</td>
<td>25–28 1 yr</td>
<td>No significant differences in the mental, motor, or gross neurologic outcome in the treated and nontreated infants</td>
</tr>
<tr>
<td>Amato et al.(^{50}) (1988)</td>
<td>L-T4 50 μg/dose, iv, 1 and 24 hr after birth</td>
<td>29–34 Short term</td>
<td>No differences in mortality, peak FIO2, ventilation days</td>
</tr>
<tr>
<td>Smith et al.(^{50}) (2000)</td>
<td>L-T4, 10 μg/kg, iv or 20 μg/kg, PO Treated (29), Untreated (18)</td>
<td>&lt;32 Short term</td>
<td>No significant difference in incidence of chronic lung disease or other complication of prematurity</td>
</tr>
<tr>
<td>Biswas et al.(^{50}) (2003)</td>
<td>T3, continuous iv, 6 μg/kg/day Treated (125), Untreated (128)</td>
<td>&lt;30 Short term</td>
<td>No difference in mortality and ventilator dependence in the first 2 wk, no difference in BPD, cerebral ultrasound findings</td>
</tr>
<tr>
<td>van Wassenaer et al.(^{50}) (1997)</td>
<td>L-T4 8 μg/kg, iv (100) Treated (100)</td>
<td>&lt;30 2 yr</td>
<td>GA &lt; 27 wk: favorable outcome in T4 treated group GA &gt; 27 wk: favorable outcome in placebo group</td>
</tr>
<tr>
<td>van Wassenaer et al.(^{50}) (2002)</td>
<td></td>
<td>5.7 yr</td>
<td>GA &lt; 29 wk: favorable outcome in T4 treated group GA &gt; 29 wk: more problem in T4 treated group</td>
</tr>
<tr>
<td>van Wassenaer et al.(^{50}) (2005)</td>
<td></td>
<td>10.5 yr</td>
<td>GA &lt; 27 wk: better school outcome GA &lt; 28 wk: better motor outcome GA &gt; 29 wk: unfavorable outcome</td>
</tr>
<tr>
<td>van Wassenaer-Leemhuis et al.(^{50}) (2014)</td>
<td>Placebo (13) Iodine (14) L-T4 bolus 4 μg/kg/day (10) L-T4 continuous 4 μg/kg/day (18) L-T4 bolus 8 μg/kg/day (11) L-T4 continuous 8 μg/kg/day (15) L-T4 bolus 16 μg/kg/day (3) L-T4 continuous 16 μg/kg/day (5)</td>
<td>&lt;28 36 mo</td>
<td>No differences in neurodevelopment were found in relation to thyroid hormone</td>
</tr>
</tbody>
</table>

GA, gestational age; L-T4, levo-thyroxine; IM, intramuscular injection; iv, intravenous infusion; PO, per oral; BPD, bronchopulmonary dysplasia
The daily iodine requirement of preterm infants is more than twice that of term infants, and studies conducted in Europe have demonstrated that most preterm infants have iodine deficiency. On the other hand, iodine excess is associated with delayed TSH elevation in the preterm infant. Since sodium/iodide symporters are expressed in the mammary gland, excessive iodine in the lactating mother can be directly transferred to the infant. The skin of preterm infants is thin and may absorb iodine easily, and preterm infants have many opportunities of exposure to iodine-containing disinfectants. Since downregulation of the sodium/iodide symporter (i.e., escape from the Wolff-Chaikoff effect) does not occur in the fetus until the third trimester and seems to appear at >35-week GA in preterm infants, thyroid function in preterm infants is vulnerable to excessive iodine intake. Dopamine is known to suppress thyrotropin release, and transfusion may affect thyroid function test results.

2. Screening for congenital hypothyroidism in preterm infant

As routine neonatal screening for congenital hypothyroidism may fail to detect the atypical form of hypothyroidism with delayed TSH elevation, recent screening guidelines recommend repeated screening in the preterm infant. The repeat specimen should be collected at either 2 weeks of age, or 2 weeks after the first screening test was carried out. However, repeat screening has not been adopted by all screening programs, because elevated TSH is mostly a transient problem. Further studies on the etiology and developmental outcomes of delayed TSH elevation are needed for better clinical practice.

Conclusions

Adrenal and thyroid hormones play various roles in somatic development and maintenance of homeostasis throughout the fetal and neonatal periods. Whereas abnormal clinical findings associated with adrenal or thyroid dysfunction are not rare in preterm infants, the diagnostic criteria and optimal management have not been determined yet. Further understanding of fetal and perinatal adrenal and thyroid function will enhance clinician insight into the management of adrenal and thyroid dysfunction in the preterm infant. Further research is required to improve the understanding of the pathophysiology and management of adrenal and thyroid dysfunction in the preterm infant.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

21. De Nayer P, Cornette C, Vanderschueren M, Eggermont E, Devlieger...
Adrenal and thyroid function in the fetus and preterm infant

60. van Wassenaar AG, Kok JH. Hypothyroxinaemia and thyroid function after preterm birth. Semin Neonatol 2004;9:3-11.
68. van Wassenaer AG, Stulp MR, Valianpour F, Tamminga P, Ris Stalpers C, de Randamie JS, et al. The quantity of thyroid hormone in human milk is too low to influence plasma thyroid hormone levels in the very preterm infant. Clin Endocrinol (Oxf) 2002;56:621-7.